The transition from the fed to the fasted state necessitates a shift from carbohydrate to fat metabolism that is thought to be mostly orchestrated by reductions in plasma insulin concentrations. Here, we show in awake rats that insulinopenia per se does not cause this transition but that both hypoleptinemia and insulinopenia are necessary. Furthermore, we show that hypoleptinemia mediates a glucosefatty acid cycle through activation of the hypothalamic-pituitary-adrenal axis, resulting in increased white adipose tissue (WAT) lipolysis rates and increased hepatic acetyl-coenzyme A (CoA) content, which are essential to maintain gluconeogenesis during starvation. We also show that in prolonged starvation, substrate limitation due to reduced rates of glucose-alanine cycling lowers rates of hepatic mitochondrial anaplerosis, oxidation, and gluconeogenesis. Taken together, these data identify a leptin-mediated glucose-fatty acid cycle that integrates responses of the muscle, WAT, and liver to promote a shift from carbohydrate to fat oxidation and maintain glucose homeostasis during starvation.
INTRODUCTION
The neocortex is one of the crowning achievements of evolution, and mammals have evolved robust mechanisms to maintain sufficient substrate supply to meet the prodigious energy demands of the brain during starvation. Chief among them is a shift from carbohydrate to fat metabolism to preserve essential protein stores necessary for survival that would otherwise be catabolized for gluconeogenesis (Cahill, 1970) . In the transition from the fed to the early fasted state, there is a shift from substrate absorption to hepatic glycogenolysis and de novo synthesis of glucose from non-carbohydrate precursors, such as lactate, alanine, and glycerol (gluconeogenesis) (Benedict, 1915; Felig et al., 1969; Rothman et al., 1991) . In contrast, in the prolonged fasted state, when hepatic glycogen stores have been depleted, hepatic gluconeogenesis and ketogenesis supply substrate to the brain and other obligate glucose utilizers, such as erythrocytes and the renal medulla. The shift from glucose metabolism to fat and ketone metabolism is thought to be primarily orchestrated by a decrease in plasma insulin concentrations and, to a lesser extent, an increase in plasma glucagon concentrations, which in turn are thought to modulate hepatic gluconeogenesis principally by the transcriptional regulation of key unidirectional enzymes, such as phosphoenolpyruvate carboxykinase (PEPCK), fructose 1,6-bisphosphatase and glucose-6-phosphatase by forkhead box protein O1 (FOXO1), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1a), hepatocyte nuclear factor-4 alpha (HNF-4a), and other factors.
Prolonged starvation has also been shown to reduce plasma leptin concentrations in both humans and mice, which in turn has been shown to alter reproductive, thyroid, and adrenal function (Ahima et al., 1996; Chan et al., 2003) . However, the effect of starvation-induced hypoleptinemia on glucose and fat metabolism has not been conclusively demonstrated. In this regard, we hypothesized that hypoleptinemia may be a critical signal to increase white adipose tissue (WAT) lipolysis through activation of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in increased hepatic acetyl-CoA content and pyruvate carboxylase activity, thereby maintaining glucose homeostasis and increasing hepatic ketogenesis during starvation.
In order to address this hypothesis, we utilized a novel positional isotopomer nuclear magnetic resonance (NMR) tracer analysis (PINTA) method (Perry et al., 2017b) to assess in vivo rates of mitochondrial pyruvate carboxylase flux (V PC ) and mitochondrial oxidation (V CS ) along with stable isotope infusions to assess rates of whole-body glucose turnover, WAT lipolysis, hepatic ketogenesis, glucose-alanine cycling, and glucose-lactate cycling in awake rats during the transition from the fed state to the prolonged fasted state. Using this comprehensive metabolic approach, we show here that hypoleptinemia drives a glucose-fatty acid cycle mediated by activation of the hypothalamic-pituitary-adrenal axis, resulting in increased rates of WAT lipolysis, b-oxidation, ketogenesis, and hepatic acetylCoA content, which is necessary to maintain glucose homeostasis and adequate substrate supply to the brain during prolonged starvation. 
RESULTS

Depletion of Hepatic Glycogen during Starvation
Induces Hypoleptinemia, which Stimulates the HPA Axis and Promotes the Transition from Whole-Body Glucose Oxidation to Fat/Ketone Oxidation Following food removal, plasma glucose concentrations progressively declined despite minimal differences in body weight and rats were found to be post-absorptive at 8 hr of fasting, as indicated by the absence of a glucose concentration gradient between the portal vein and the jugular vein ( Figures 1A, S1A , and S1B). This progressive reduction in plasma glucose concentrations in the early post-absorptive state (8-16 hr) could be entirely attributed to reductions in rates of net hepatic glycogenolysis, as reflected by the strong correlation between plasma glucose concentrations and rates of net hepatic glycogenolysis (R 2 = 0.96, p = 0.003) (Figures 1B and S1C-S1F). In contrast, plasma glucose concentrations were dissociated from rates of hepatic gluconeogenesis, which increased between 8 and 16 hr but decreased between 16 and 48 hr (Figure 1B) . In addition, the progressive reduction in rates of net hepatic glycogenolysis during the fast was associated with a shift from glucose to fat/ketone oxidation, demonstrated by fasting duration-dependent reductions in the ratio of pyruvate dehydrogenase flux to citrate synthase flux (V PDH /V CS ) in liver, kidney (cortex), skeletal muscle, WAT, brown adipose tissue (BAT), heart, and brain ( Figure 1C ). Plasma non-esterified fatty acid (NEFA), glycerol, and b-hydroxybutyrate (b-OHB) concentrations increased progressively throughout the fast (Figures S1G-S1I). Interestingly, during starvation, plasma triglyceride (TAG) concentrations were reduced at 48 hr of fasting, whereas liver TAG and diacylglycerol (DAG) content were increased. This increase in hepatic DAG content was associated with increased protein kinase C-epsilon (PKCε) translocation (Figures S1J-S1M), which in turn was associated with reduced percent suppression of endogenous glucose production during a hyperinsulinemic-euglycemic clamp ( Figures  S1N-S1P ). The dissociation between plasma and liver TAG can likely be explained in part by increased hepatic esterification of fatty acids into hepatic TAG driven by increased WAT lipolysis combined with reduced hepatic TAG export, which may be in part attributed to reductions in liver apolipoprotein B (ApoB) concentrations ( Figure S1Q ). Similarly, skeletal muscle TAG content increased in fasted rats as the fast progressed ( Figure S1R ). In addition, there was no change in peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1a) expression with starvation, and gluconeogenic enzyme (phosphoenolpyruvate carboxykinase, pyruvate carboxylase, glucose-6-phosphatase) expression did not correlate with the measured changes in gluconeogenic flux (Figures S1S-S1W).
Not surprisingly, the reduction in plasma glucose concentrations that occurs as the fast progresses was accompanied by reductions in plasma insulin concentrations and increases in plasma glucagon concentrations (Figures S2A and S2B) . Plasma leptin concentrations decreased by 80% between fed and 48-hr fasted rats; this was associated with activation of the HPA axis, as indicated by increases in plasma corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and corticosterone concentrations ( Figures 1D, 1E , S2C, and S2D). Corticosteroid-binding globulin also increased modestly, but there were no differences in plasma epinephrine or norepinephrine concentrations and a transient increase in plasma growthhormone concentration after a short-term, but not a long-term, fast . Consistent with previous reports, starvation was also associated with an increase in plasma fibroblast growth factor-21 (FGF-21) concentrations (Kim and Lee, 2014; Kliewer and Mangelsdorf, 2010 ) ( Figure S2I ) and a reduction in plasma triiodothyronine (T 3 ) concentrations (Flier et al., 2000) ( Figure S2J ). In contrast to in lean-chow-fed rats, plasma leptin, corticosterone, NEFA, and ketone concentrations did not change significantly with a 48-hr fast in hyperleptinemic, dietinduced obese rats ( Figures S2K-S2N) .
Next, to more specifically investigate the impact of reductions in net hepatic glycogenolysis on rates of endogenous glucose production, plasma leptin concentrations, and activation of the HPA axis, we treated post-absorptive rats fasted for 8, 16, and 48 hr with a small molecule inhibitor of glycogen phosphorylase and found that inhibition of hepatic glycogenolysis lowered plasma glucose, lactate, and insulin concentrations and wholebody glucose turnover in the short-term (8 and 16 hr) fasted rats, but not in the 48-hr fasted rats, consistent with the negligible contributions that hepatic glycogenolysis would be expected to have on plasma glucose concentrations in this glycogen-depleted state . Interestingly, the reductions in plasma glucose and insulin concentrations in 8-and 16-hr fasted rats treated with the glycogen phosphorylase inhibitor were associated with reductions in plasma leptin concentrations and increases in HPA axis activity, as reflected by increases in plasma corticosterone and ACTH concentrations in these groups ( Figures 1G, 1H , and S2S). In contrast, plasma glucagon and catecholamine concentrations were not altered by treatment with the glycogen phosphorylase (B) Hepatic glucose production from net hepatic glycogenolysis, gluconeogenesis from oxaloacetate (i.e., V PC ), and gluconeogenesis from glycerol. *p < 0.05 versus 8-hr fasted rats and xxxxp < 0.0001 versus 16-hr fasted rats, in both cases comparing gluconeogenesis from oxaloacetate. (C) Percent glucose oxidation in the TCA cycle (pyruvate dehydrogenase flux [V PDH ]/citrate synthase flux [V CS ]). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 versus fed rats; ####p < 0.0001 versus 6-hr fasted rats; and xp < 0.05 and xxp < 0.01 versus 16-hr fasted rats. (D and E) Plasma leptin (D) and corticosterone (E) concentrations. (F) Endogenous glucose production before and 2 hr after treatment with a glycogen phosphorylase inhibitor. (G and H) Plasma leptin (G) and corticosterone (H) concentrations in glycogen phosphorylase inhibitor-treated rats. In (F-H), data from the same rats before and after treatment with the inhibitor were compared by the paired Student's t test; in all other panels, ANOVA with Bonferroni's multiple comparisons test was used. Data are the mean ± SEM of n = 6-8 per group. See also Figures S1 and S2.
inhibitor, despite increased plasma FGF-21 concentrations in 8-and 16-hr fasted rats ( Figures S2T-S2W ).
Physiologic Leptin Replacement Suppresses Lipolysis and Reduces Plasma Glucose, but Supraphysiologic Leptin Stimulates Lipolysis and Increases Plasma Glucose Next, we sought to understand the physiologic role of the reductions in plasma leptin concentrations associated with prolonged starvation on the HPA axis, WAT lipolysis, and hepatic gluconeogenesis. To address this question, we infused leptin in 48-hr fasted rats at 3 infusion rates designed to increase plasma leptin to physiologic concentrations observed in a 16-hr fast ($60 pM) to concentrations similar to those observed in obese rats (Figure S2K) and in fed rats ($150 pM) and to supraphysiologic concentrations ($1250 pM) similar to or lower than those measured with leptin infusion in previous reports (Morton et al., 2015; Ravussin et al., 2014; Shek et al., 1998) (Figure 2A ). We found that physiologic leptin replacement ($60 pM) lowered plasma glucose concentrations and hepatic glucose production, requiring an infusion of glucose to prevent hypoglycemia and counter-regulation; however, infusions of leptin to raise plasma leptin concentrations to $150 pM and $1250 pM were unable to lower either parameter ( Figures 2B, 2C , and S3A). The reductions in plasma glucose concentrations with physiologic leptin replacement (plasma leptin concentration, $60 pM) and increases in plasma glucose concentrations with supraphysiologic leptin treatment (plasma leptin concentrations, $150 pM and $1250 pM) were mirrored in suppression of plasma NEFA, glycerol, b-OHB, and lactate concentrations with physiologic leptin replacement and increases with supraphysiologic leptin infusions ( Figures S3B-S3E ). Consistent with leptin's effect to suppress HPA axis activity, plasma corticosterone was suppressed by all three infusion rates of leptin. However, plasma catecholamine concentrations increased dose dependently with increasing leptin infusion, with the highest infusion rate of leptin raising plasma epinephrine and norepinephrine concentrations 2-to 3-fold ( Figures 2D-2F ). Plasma insulin concentrations also increased at the highest dose of leptin, most likely secondary to the increased rates of hepatic glucose production and resultant hyperglycemia; in contrast, there was no difference in plasma growth hormone concentrations (Figures S3F and S3G) . However, leptin infusion caused a dose-dependent reduction in plasma FGF-21 concentrations, suggesting that the increase in plasma FGF-21 concentrations observed in fasted rats is secondary to hypoleptinemia and the resulting changes in the HPA axis, WAT lipolysis, and hepatic fat oxidation (Figure S3H) . As predicted by the changes in plasma corticosterone and catecholamines, both fatty acid and glycerol turnover were suppressed with physiologic leptin replacement in 48-hr fasted rats and increased with supraphysiologic leptin treatment, resulting in increases in hepatic acetyl-CoA content and b-OHB turnover .
To examine the potential insulin dependence of the ability of leptin to suppress HPA-axis-mediated WAT lipolysis under physiologic conditions but promote WAT lipolysis under supraphysiologic conditions due to increases in plasma catecholamine concentrations, we performed leptin dose-response studies in a severely insulinopenic streptozotocin-induced rat model of type 1 diabetes (T1D) that almost entirely lack plasma leptin (Perry et al., 2016) . Similar to what we observed in the starved normal rats, we found that physiologic leptin replacement ($60 pM) in the T1D rats promoted a marked reduction in plasma glucose concentrations and endogenous glucose production rates, but supraphysiologic leptin concentrations ($1300 pM) promoted increases in both plasma glucose concentrations and endogenous glucose production ( Figures  S3J-S3M ). Both doses of leptin suppressed HPA axis activity, but supraphysiologic leptin concentrations ($1300 pM) were associated with a 4-fold increase in plasma catecholamine concentrations without any change in growth hormone concentrations ( Figures S3N-S3R ). These alterations in HPA axis activity and catecholamine concentrations were associated with suppression of WAT lipolysis in T1D rats infused with leptin to achieve physiologic replacement leptin concentrations ($60 pM), an effect which was abrogated in rats infused with leptin to reach supraphysiologic plasma leptin concentrations ($1300 pM) ( Figures S3S-S3U ). Figures 3A-3C and S4A). As predicted by the increase in b-OHB turnover observed with increasing duration of fasting (Perry et al., 2017c) , hepatic acetyl-CoA concentrations also increased as the fast progressed, whereas hepatic malonyl-CoA content was reduced by 75% between 6 and 16 hr of fasting, but did not change between the 16 and 48 hr time points ( Figures 3D and 3E ), suggesting that inhibition of carnitine palmitoyltransferase-1 (CPT-1) activity by hepatic malonyl-CoA content reached a nadir by 16 hr of fasting (McGarry et al., 1978; Saggerson and Carpenter, 1981) . Next, to directly assess the impact of increases in hepatic acetyl-CoA content on hepatic glucose metabolism, we treated rats fasted for 0, 6, 16, and 48 hr with etomoxir, a small-molecule inhibitor of CPT-1. We found that in fasted rats, CPT-1 inhibition lowered plasma glucose and insulin concentrations and wholebody glucose turnover associated with suppression of hepatic acetyl-CoA content and b-OHB turnover despite increased WAT lipolysis-which was likely a consequence of the reductions in plasma insulin concentrations observed with inhibition of CPT-1-and unchanged plasma lactate and hepatic malonyl-CoA concentrations . To examine whether the reductions in plasma glucose and insulin measured with CPT-1 inhibition were associated with alterations in HPA axis activity, we measured plasma leptin and corticosterone concentrations and found that etomoxir treatment was associated with 50% reductions in plasma leptin concentrations, as well as increases in plasma corticosterone concentrations in 16-and 48-hr fasted rats ( Figure 3I and 3J ). In contrast, there In (A-E), n = 7 per time point, and data were compared by ANOVA with Bonferroni's multiple comparisons test. In (F-J), data are the mean ± SEM of n = 6 per group. Data were compared by ANOVA with Bonferroni's multiple comparisons test (control versus etomoxir versus atglistatin, with these groups compared separately at each time point; control data are duplicated in and Figures 3 and 4) . See also Figure S4 .
Increases in Leptin
were no differences in plasma epinephrine or norepinephrine concentrations ( Figures S4K and S4L) .
Next, to more directly assess the role of increased WAT lipolysis in the maintenance of hepatic gluconeogenesis by hepatic acetylCoA in starvation, we treated rats with atglistatin, a small molecule inhibitor of adipose triglyceride lipase (ATGL). Atglistatin treatment rapidly decreased plasma glucose concentrations in 16-and 48-hr fasted rats, and an infusion of glucose was required to avoid severe hypoglycemia due to suppression of WAT lipolysis and hepatic acetyl-CoA content in the latter group, despite unchanged plasma lactate, epinephrine, and norepinephrine con- centrations and hepatic malonyl-CoA content (Figures 4A-4F and S5A-S5I). As in etomoxir-treated rats, 16-and 48-hr fasted, atglistatin-treated rats exhibited reductions in plasma leptin and increases in plasma corticosterone concentration (Figures 4G and 4H) , consistent with plasma glucose/ insulin regulation of leptin release from the adipocyte. Next, to assess whether increased plasma corticosterone concentrations are necessary to maintain euglycemia in the starved state, we treated rats with a glucocorticoid receptor antagonist, mifepristone. Despite infusion of glucose to avoid hypoglycemia provoking a counterregulatory response, mifepristone treatment decreased plasma glucose concentrations, whole-body glucose turnover, WAT lipolysis, and ketogenesis in 48-hr fasted rats, but not in recently fed rats . Finally, consistent with data in rats treated with etomoxir and atglistatin, the lower plasma glucose and insulin concentrations caused by treating 48-hr fasted rats with mifepristone were associated with a 60% reduction in plasma leptin concentrations ( Figure 5H ). Taken together, these data demonstrate the key role for hepatic acetyl-CoA in supporting hepatic gluconeogenesis during starvation. Furthermore, they demonstrate the critical role for hypoleptinemia-mediated increases in HPA axis activity in promoting increased WAT lipolysis and hepatic ketogenesis in this process.
Reductions in Muscle Glucose-Alanine Cycling Promote Decreased Rates of Hepatic Mitochondrial Oxidation and Gluconeogenesis in the Prolonged (48 hr) Fasted State Given the progressive increases in WAT lipolysis and hepatic acetyl-CoA content with increasing duration of the fast, it might be expected that hepatic pyruvate carboxylase flux (V PC ) would also continue to increase with an extended fast. Surprisingly, we observed a $50% reduction in pyruvate carboxylase flux between 16-and 48-hr fasted rats ( Figure 1B) , despite a 15% increase in hepatic acetyl-CoA content during this time interval ( Figure 3D ). To understand the reasons for the discordance between hepatic pyurvate carboxylase flux and hepatic acetyl-CoA content, we assessed plasma concentrations and turnover rates of the two In all panels, data are the mean ± SEM of n = 6, with data from before and after mifepristone treatment compared by the two-tailed paired Student's t test. See also Figure S6 .
predominant gluconeogenic substrates (lactate and alanine) and observed 65% reductions in rates of whole-body alanine turnover, as well as 35% reductions in hepatic alanine concentrations between 16-and 48-hr fasted rats, associated with smaller reductions in lactate turnover and plasma amino acid concentrations . Surprisingly, PINTA analysis of hepatic mitochondrial oxidation rates also revealed a 50% reduction in rates of hepatic mitochondrial oxidation (V CS ) associated with reductions in liver citrate, malate, and succinate concentrations. Taken together, these data suggest that prolonged (48 hr) starvation leads to reductions in glucose-alanine cycling, which in turn results in decreased hepatic mitochondrial anaplerosis via pyruvate carboxylase, resulting in decreased rates of mitochondrial oxidation ( Figures 6B, 6C , and S7M-S7O). To test this hypothesis, we infused alanine in 48-hr fasted rats to match alanine turnover rates and hepatic alanine concentrations measured in 16-hr fasted rats (Figures S7P and S7Q) . This intervention increased plasma glucose, insulin, and lactate concentrations; endogenous glucose production; and pyruvate carboxylase flux (V PC ) associated with a 3-fold increase in plasma leptin concentrations but independent of any change in plasma glucagon (Figures 6D-6F and S7R-S7U). In addition, normalizing alanine turnover increased liver tricarboxylic acid cycle intermediate concentrations and rates of hepatic mitochondrial oxidation (V CS ) in 48-hr fasted rats independent of changes in plasma T 3 concentrations (Figures 6G, 6H, and S7V-S7Y).
Small Reductions in Plasma Glucose (6-5 mM) Suppress Muscle Glucose-Alanine Cycling during Prolonged (48 hr) Starvation Finally, we sought to test the hypothesis that subtle reductions in plasma glucose concentrations from 6 to 5 mM promote hypoleptinemia, increased HPA axis activity, and reductions in glucose-alanine cycling, as well as glucose-lactate cycling in the starved state. To that end, we performed a low-dose glucose infusion in 48-hr fasted rats to increase plasma glucose concentrations from 5 to 6 mM, as measured in 16-hr fasted rats (Figures S8A and S8B) . This intervention increased plasma insulin concentrations by 75% and doubled plasma lactate concentrations while reducing plasma FGF-21 concentrations by 50%. Likely due to the increase in plasma insulin concentrations, plasma NEFA concentrations and rates of endogenous glucose production were also reduced by 30-50% (Figures 7A, 7B, and S8C-S8E). Increasing plasma glucose from 5 to 6 mM doubled both glucose uptake into skeletal muscle and whole-body alanine turnover ( Figures 7C and 7D ), increasing the latter to rates similar to those observed in 16-hr fasted rats. In addition, 48-hr fasted rats with plasma glucose concentrations $6 mM exhibited a 2-fold increase in WAT glucose uptake as compared to 48-hr fasted rats with plasma glucose $5 mM, doubling plasma leptin concentrations and suppressing HPA axis activity as reflected by 50%-60% reductions in plasma ACTH and corticosterone concentrations . Similarly, we found that treatment of short-term fasted rats (8 and 16 hr) with an inhibitor of glycogen phosphorylase resulted in hypoleptinemia and increased HPA axis activity, as well as increased rates of WAT lipolysis and decreased rates of alanine turnover ( Figures 7I, 7J , and S8F-S8J).
DISCUSSION
To prolong survival during an extended fast, mammals must shift from a primary reliance upon carbohydrate metabolism to a primary reliance upon fat and ketone metabolism in order to maintain adequate substrate supply to the brain, heart, and other organs, thus preserving essential protein stores that would otherwise be catabolized to support gluconeogenesis (Cahill, 1970) . While insulin and, to a lesser extent, glucagon have long been thought to be the major orchestrators of this transition from glucose to fat/ketone metabolism, here, we demonstrate a leptin-mediated glucose-fatty acid cycle that is essential to support this process. Consistent with previous in vivo 13 C nuclear magnetic resonance studies of hepatic glycogen metabolism in humans (Rothman et al., 1991) , we found that the fraction of glucose production from hepatic glycogenolysis decreases over the course of a 48-hr fast in lean rats, while gluconeogenesis rates remain relatively constant until rats reach a state of prolonged starvation at 48 hr, whereupon gluconeogenic flux decreases by $50%. Similar to data from fasting humans, hepatic glycogen concentrations in rats followed a pattern of exponential decay during fasting ( Figure S1D ), and the reduction in rates of net hepatic glycogenolysis was the major determinant of the reduction in the rate of endogenous glucose production and plasma glucose concentration observed during a prolonged fast ( Figures  1A-1C ). To specifically test the physiologic impact of reductions in rates of hepatic glycogenolysis on leptin secretion, HPA axis activity, and WAT lipolysis, we treated rats with a small molecule inhibitor of glycogen phosphorylase. Consistent with a key role for hepatic glycogenolysis as the major determinant of endogenous glucose production and fasting plasma glucose concentrations in the early stages (0 to 16 hr) of the fast, 8-and 16-hr fasted rats treated with the glycogen phosphorylase inhibitor manifested rates of endogenous glucose production that were reduced by 60% and 30%, respectively ( Figure 1F ). In contrast, 48-hr fasted rats treated with the glycogen phosphorylase inhibitor exhibited no difference in rates of endogenous glucose production, consistent with rates of net hepatic glycogenolysis being negligible by 48 hr of fasting. In order to examine the ability of reductions in hepatic glycogenolysis to drive the HPA activation observed in the starved state, we assessed plasma lipolytic hormone concentrations and WAT lipolysis in rats treated with an inhibitor of glycogen phosphorylase. We observed a reduction in plasma leptin concentrations and increases in plasma corticosterone concentrations and WAT lipolysis, bringing each parameter to concentrations measured in 48-hr fasted rats despite unchanged plasma catecholamine concentrations in short-term fasted rats treated with the glycogen phosphorylase inhibitor ( Figure 1G , 1H, 7J, S2S, S2U, S2V, and S8F-S8J). These results suggest that hypoleptinemia-driven HPA axis activation could promote increased hepatic gluconeogenic flux by increasing WAT lipolysis, resulting in increased fatty acid delivery to liver and hepatic acetyl-CoA content to maintain euglycemia during prolonged (R 16 hr) fasting. Consistent with this hypothesis, we found that both WAT lipolysis and hepatic acetyl-CoA content increased with increasing duration of the fast. Interestingly, these increases in WAT lipolysis were also associated with the development of severe hepatic steatosis, increases in hepatic DAG content, hepatic PKCε activation, and impaired percent suppression of endogenous glucose production during a hyperinsulinemic-euglycemic clamp ( Figures S1K-S1P ). These results are consistent with prior studies demonstrating that increased fatty acid delivery to the liver can promote increased hepatic esterification and hepatic TAG synthesis in an insulin-independent fashion (Vatner et al., 2015) , as well as a causal role for hepatic DAG activation of PKCε in hepatic insulin resistance, through increased insulin receptor kinase threonine 1160 (murine 1150) phosphorylation (Petersen et al., 2016; Samuel et al., 2004 Samuel et al., , 2007 .
In contrast to ectopic lipid content, which increased progressively through the fast, hepatic malonyl-CoA decreased between 6 and 16 hr of the fast, facilitating mitochondrial b-oxidation by reducing inhibition of CPT-1. To further examine the potential role of increasing hepatic acetyl-CoA concentrations in the maintenance of hepatic gluconeogenesis and endogenous glucose production, we treated rats with two agents to directly modulate hepatic acetyl-CoA content: ATGL inhibitor atglistatin and CPT-1 inhibitor etomoxir. Despite different mechanisms of action, both agents suppressed hepatic acetyl-CoA content, hepatic gluconeogenesis, and plasma glucose and insulin concentrations in 16-to 48-hr fasted rats, thus demonstrating a critical role for hepatic acetyl-CoA content in the maintenance of hepatic gluconeogenesis during starvation.
Taken together, these data challenge the canonical view of the primacy of insulinopenia-mediated transcriptional and/or translational regulation of gluconeogenic enzymes in increasing hepatic gluconeogenesis and maintaining euglycemia in starvation. Although PEPCK protein expression increased progressively during the fast, hepatic gluconeogenesis from oxaloacetate was reduced by 50% from 16 to 48 hr due to substrate limitation ( Figures 1B, 6E , and 6F) in the setting of unchanged pyruvate carboxylase protein expression. These data raise the question of whether insulinopenia per se promotes WAT lipolysis and increases in hepatic acetyl-CoA content in the starved state or whether other factors such as HPA axis activation ( Figure 1D ) are also required.
To answer that question, we first administered mifepristone, a selective glucocorticoid receptor antagonist, to rats fasted for 6 and 48 hr. Although mifepristone had no impact on WAT lipolysis, whole body glucose turnover, or plasma glucose or insulin concentrations in recently fed rats (6 hr), inhibition of glucocorticoid action markedly suppressed each of these parameters, necessitating glucose infusion to avoid severe hypoglycemia and counter-regulation in prolonged (48 hr) fasted rats ( Figure 5 ).
Because mifepristone treatment suppressed WAT lipolysis in the setting of reductions in plasma insulin concentrations, these data suggest that severe insulinopenia per se is not sufficient to promote increased WAT lipolysis and hepatic gluconeogenesis in starved rats. To further test the role of HPA axis activation and, specifically, the role of hypoleptinemia in driving this process, we infused leptin in a stepwise fashion to increase plasma leptin concentrations in 48-hr fasted rats to: (1) physiologic concentrations typical of overnight-fasted, chow-fed rats ($60 pM), (2) modestly elevated concentrations similar to those of high-fatfed (HFD) rats ($150 pM) ( Figure S2K ), and (3) supraphysiologic concentrations ($1300 pM) similar to or lower than those measured in previous systemic leptin infusion studies in the literature (Morton et al., 2015; Ravussin et al., 2014; Shek et al., 1998) . This study demonstrated that physiologic leptin replacement suppressed HPA axis activity, WAT lipolysis, hepatic acetyl-CoA content, and rates of hepatic gluconeogenesis in 48-hr fasted rats without altering plasma insulin concentrations, thereby demonstrating that insulinopenia per se is not sufficient to increase WAT lipolysis, hepatic acetyl-CoA content, and hepatic gluconeogenesis during starvation.
To further examine the role of insulin in mediating leptin's effect on WAT lipolysis, we performed leptin dose-response studies in a severely insulinopenic streptoztocin-induced rat model of T1D that is also severely leptinopenic (Perry et al., 2014 (Perry et al., , 2017a ). These data demonstrate the impact of the absence of leptin: with plasma leptin concentrations only $12 pM (92% lower than fed rats) and severe insulinopenia (99% lower than fed rats), both WAT lipolysis and endogenous glucose production rates were markedly increased, but again, we found that physiologic leptin replacement suppressed endogenous glucose production and WAT lipolysis in T1D rats ( Figures S3J-S3U) , consistent with previous studies (Perry et al., 2014 (Perry et al., , 2017a . However, in both fasting normal control rats and T1D rats, supraphysiologic leptin concentrations promoted increased catecholamine release, increasing WAT lipolysis and abrogating leptin's effect to lower rates of endogenous glucose production and plasma glucose concentrations. These data are consistent with prior studies demonstrating that leptin activates catecholamine synthesis (Shibuya et al., 2002) , catecholamine signaling (Luan et al., 2014) , and energy expenditure (Levin et al., 1996; Pelleymounter et al., 1995) . Further, the ability of leptin to stimulate the sympathetic nervous system, WAT lipolysis, and hepatic glucose production at plasma concentrations R 150 pM may explain the failure of previous studies (Denroche et al., 2011 (Denroche et al., , 2015 Morton et al., 2015) to observe an effect of leptin to reduce hyperglycemia in fasted insulinopenic diabetic In (C) and (E), data were compared by the two-tailed unpaired Student's t test; otherwise, the paired t test was used. Data are the mean ± SEM of n = 6-7 per group. See also Figure S8 . rodents through suppression of HPA axis activity. In addition, hypoleptinemia-induced activation of HPA axis activity may not occur universally in starvation as we observed in 4-week HFD obese rats (Figures S2K-S2N) . In contrast to regular chow-fed lean control rats, we found that HFD obese hyperleptinemic rats do not manifest reductions in plasma leptin concentrations and increases in HPA activity during 48 hr of fasting ( Figures  S2K-S2N ). This may explain why starvation-induced reductions in plasma leptin concentrations and increases in HPA activity have not always been observed in human studies: in contrast to young lean rodents, which have minimal fat mass after a 48-hr fast, most normal weight human subjects will still have substantial fat mass even after several days of starvation, which would not be expected to decrease plasma leptin concentrations to the critical threshold that maybe required to activate the HPA axis. In contrast, patients with anorexia nervosa often develop severe hypoleptinemia (due to depleted fat stores) which is associated with activation of the HPA axis and hypercortisolemia (Schorr and Miller, 2017) , suggesting that under conditions of severe depletion of adipose tissue mass, leptin may decrease sufficiently with starvation to activate HPA axisdriven WAT lipolysis. In contrast, in overweight subjects or those undergoing caloric restriction instead of fasting in whom leptin may not be reduced sufficiently to produce increased HPA activity, this mechanism may not be as relevant or may take a longer time to occur in order to deplete the larger fat mass in these overweight/obese individuals. Consistent with this possibility, several recent studies do show an association between hypoleptinemia and increased plasma cortisol concentrations in high-normal weight humans during caloric deprivation (Karl et al., 2016; Pasiakos et al., 2011; Villareal et al., 2016) . In addition, it is possible that the relative importance of insulinopenia-and hypoleptinemia-induced HPA axis activation in driving the shift from glucose to fat metabolism may differ between rodents and humans; in contrast to rodents, insulinopenia may be sufficient to produce most or all of the effect of starvation to increase WAT lipolysis in humans independent of increases in plasma cortisol concentrations (Jensen et al., 1989) .
Several reports suggest that in lean and obese human subjects, plasma leptin concentrations decrease during caloric restriction out of proportion to the decline in total body weight or fat mass and increase with refeeding or long-term hyperinsulinemia (Ahima and Lazar, 2008; Hintze et al., 2017) , consistent with our data (Figures 1D, 7F , and S1A). These data pose the question of whether starvation regulates plasma leptin concentrations by an alternative mechanism in addition to reductions in total fat mass. Consistent with this possibility, acute treatment with inhibitors of glycogen phosphorylase, CPT-1, ATGL, and the glucocorticoid receptor all reduced plasma glucose, insulin, and leptin concentrations within just 2 hr, a time frame incompatible with similar reductions in body weight. We hypothesized that a reduction in plasma glucose concentrations from 6 to 5 mM and consequent reductions in plasma insulin concentrations from $100 to $45 pM during prolonged fasting-of which we have shown results primarily from depletion of hepatic glycogen stores ( Figures 1F,  S2P , and S2Q)-reduce plasma leptin concentrations from $65 to $35 pM. Consistent with this hypothesis, we found that a small increase in plasma glucose concentrations from 5 to 6 mM in 48-hr fasted rats doubled glucose uptake into WAT, doubled plasma leptin concentrations, and reduced plasma corticosterone concentrations by 50% (Figures 7E-7H ). These data demonstrate that progressive reductions in plasma glucose concentrations during the fed to fasted transition in lean, normal chow-fed rats signals the depletion of stored hepatic carbohydrate (glycogen) reserves and results in reduced WAT leptin secretion, which in turn stimulates the HPA axis activity to promote increased WAT lipolysis and the transition from whole body glucose oxidation to fat/ketone oxidation. Surprisingly, despite increased or unchanged WAT lipolysis and hepatic acetyl-CoA content between 16 and 48 hr of fasting, rats exhibited a $50% reduction in rates of hepatic gluconeogenesis after 48 hr of starvation, which could be entirely attributed to reductions in rates of hepatic pyruvate carboxylase flux (V PC ) between these time points ( Figure 1B) . We hypothesized that reductions in alanine turnover, which we observed in 48-hr starved rodents ( Figure 6A ) and which are consistent with previous studies demonstrating a reduction in alanine release from the forearm in fasted humans (Felig et al., 1969) , may be responsible for reduced hepatic gluconeogenesis due to substrate limitation. To test that hypothesis, we infused rats with alanine to increase total alanine turnover to match rates of alanine turnover measured in 16-hr fasted rats. This intervention increased plasma glucose and insulin concentrations, hepatic glucose production, and hepatic pyruvate carboxylase flux similar to or greater than what was measured in 16-hr fasted rats. In addition, rates of hepatic mitochondrial oxidation (citrate synthase flux, V CS )-assessed by PINTA analysis-revealed suppression of hepatic mitochondrial oxidation flux (V CS ) with 48 hr of fasting, but alanine replacement increased rates of hepatic mitochondrial oxidation (V CS ) independent of changes in plasma T 3 concentrations ( Figures S2J and S7Y) . Taken together, these data reveal that reductions in alanine turnover during prolonged starvation cause suppression of hepatic mitochondrial oxidation rates. The reductions in alanine turnover observed in the starved state would be expected to promote further increases in hepatic ketogenesis due to an expanding mismatch between rates of hepatic b-oxidation and hepatic mitochondrial oxidation (V CS ), thereby providing increased ketones to serve as a substrate for brain mitochondrial oxidative metabolism, supplying $45% of the brain's energy needs after 48 hr of starvation ( Figure 1C ). The reductions in alanine turnover observed in the starved state were confirmed to result from reductions in plasma glucose concentrations from 6 to 5 mM: infusion of glucose to raise plasma glucose concentrations from 5 to 6 mM in 48-hr fasted rats increased whole-body alanine turnover to rates similar to those measured in 16-hr fasted rats ( Figure 7D ).
In summary, these data reveal several new concepts regarding leptin biology and the regulation of whole-body and tissue-specific substrate metabolism from the transition from the fed to fasted state in normal lean free-ranging rats, specifically:
(1) Progressive decreases in plasma glucose (9 to 6 mM) and insulin (500 to 100 pM) concentrations during early starvation (6-16 hr) can mostly be ascribed to reduced rates of net hepatic glycogenolysis (25 to 4 mmol/[kg , min]) Regarding this last point, it is interesting to speculate that fasting-induced hepatic steatosis and lipid-induced hepatic insulin resistance may also play an important role in promoting survival during famine by minimizing hepatic glucose uptake and energy storage as glycogen, therefore sparing any ingested carbohydrate for the central nervous system and other obligate glucose-requiring tissues, thus providing an evolutionary basis for DAG-PKCε induced hepatic insulin resistance.
Taken together, these data show that both insulinopenia and hypoleptinemia are necessary for maintenance of euglycemia during short-term (6-16 hr) starvation in lean rats, with insufficient anaplerosis from glucose-alanine cycling limiting both hepatic gluconeogenesis and mitochondrial oxidation in prolonged (48 hr) starvation. These data further identify a novel leptin-mediated glucose-fatty acid cycle that integrates responses of the muscle, white adipose tissue, and liver to maintain adequate substrate supply to the brain to promote survival during starvation.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
All rodent studies were approved by the Yale University Institutional Animal Care and Use Committee. Male Sprague-Dawley rats were ordered from Charles River Laboratories (Wilmington, MA) at $250 g and were group housed (3 per cage) for 1-2 weeks until they underwent surgery under general isoflurane anesthesia for placement of polyethylene catheters in the common carotid artery (PE50 tubing, Instech Solomon, Plymouth Meeting, PA), and the jugular vein (PE90 tubing, Instech), and/or the portal vein (PE50 tubing, Instech), after which they were singly housed until sacrifice. Unless otherwise specified, rats were fed a regular chow diet (Harlan Teklad #2018, Indianapolis, IN) throughout, and fasted as described below. High fat fed rats were given ad lib access to a safflower oil-based high fat diet containing 60% calories from fat (Dyets #112245, Bethlehem, PA) for 4 weeks prior to sacrifice, before which they were fasted as described above. In order to induce T1D, rats were injected with streptozotocin (65 mg/kg IP, Sigma Aldrich, St. Louis, MO) 24 hr prior to the start of a leptin infusion study and were fasted overnight 12 hr after streptozotocin injection. T1D was confirmed by the combination of hyperglycemia (> 17 mM) and insulinopenia (< 30 pM) after the overnight fast; all rats that did not meet both criteria ($25% of those injected with streptozotocin) were excluded from analysis. Rats were randomly assigned to fasting time points following a 24 hr fast-refeeding protocol designed to maximize whole-body glycogen content prior to the fast, as occurs following a large meal. The feeding and fasting times for each group of rats are listed in Table S1 .
Following the fasting period designated, rats underwent studies as described in the following sections. They were euthanized with IV pentobarbital at the conclusion of each study, and their tissues rapidly freeze-clamped (liver freeze-clamped in situ) in tongs pre-cooled in liquid nitrogen.
METHOD DETAILS
Animal Studies
In all studies, rats were sacrificed with tissues and plasma collected for analysis at 14:00 hr, removing any impact of diurnal variation on the measurements taken. All tracers were infused through a catheter placed $1 week prior in the carotid artery, and blood was obtained from a catheter in the jugular vein. Measurements of portal vein glucose concentrations were performed on blood samples taken from a catheter in the portal vein; unless otherwise specified, all blood was drawn from the jugular vein. All studies began 1 hr after catheters were connected, reducing any impact of stress from handling on the physiology assessed.
Tracers
Primed-continuous infusions of tracers were performed at the following rates. In each case, the prime was for 5 min, with the continuous infusion spanning 5-120 min. Tracer infusion rates are shown in Table S2 .
A bolus of [6,6-14 C]2-deoxyglucose was administered in 48 hr fasted control rats and 48 hr fasted rats infused with glucose to increase plasma glucose concentrations to 6 mM and gastrocnemius muscle and epididymal white adipose tissue were harvested and processed to determine basal glucose uptake in both tissues by comparing the plasma [ 14 C] specific activity decay curve to tissue [
14 C] specific activity, both measured using a scintillation counter (Jurczak et al., 2012) .
Leptin Infusions
In order to examine the physiologic impact of varying doses of leptin on glucose, hormones, and lipolysis, rats were infused with stepwise increasing doses of leptin (Sigma) during a continuous infusion of [1,2,3,4,5,6, glycerol, and [U-13 C 4 ]bÀOHB starting at hour 42 of a 48 hr fast. From 42-43.5 hr of the fast rats were infused with tracer only, from hours 43.5-45 they were infused with 20 pmol/(kg-min) leptin, from hours 45-46.5 they were infused with 60 pmol/(kg-min) leptin, and from 46.5-48 hr the infusion rate was 600 pmol/(kg-min). Blood samples were taken at 43.5, 45, 46.5, and 48 hr for measurement of substrate/hormone concentrations and turnover of each tracer, as described below.
In the T1D leptin dose response studies, overnight (12 hr) fasted rats were infused with stepwise increasing dose of leptin during the same tracer infusion as described above. From 12-14 hr of the fast rats were infused with tracer only, from 14-16 hr they were infused with 50 pmol/(kg-min) leptin, and from hours 16-18 they were infused with 600 pmol/(kg-min) leptin. Blood samples were taken at 14, 16, and 18 hr of the fast for measurement of substrate/hormone concentrations and turnover of each tracer, as described below.
Pharmacologic Manipulation of Glycogen and Acetyl-CoA 8, 16, and 48 hr fasted rats were injected with a small molecule inhibitor of glycogen phosphorylase, 1-(3-(3-(2-Chloro-4,5-difluorobenzoyl)ureido)-4-methoxyphenyl)-3-methylurea (Sigma #361515; 5 mg/kg IV) and a tracer infusion of [2,3,3, Table S2 , for 120 min. Blood samples were obtained before (time zero) and 120 min after treatment with the glycogen phosphorylase inhibitor for measurement of turnover rates and plasma hormone/substrate concentrations.
Hepatic acetyl-CoA content was altered by treatment with a CPT-1 inhibitor (etomoxir, 8 mg/kg) or an ATGL inhibitor (atglistatin, 200 mmol/kg) in 0, 6, 16, and 48 hr fasted rats. Both agents were solubilized by suspending the drug in 4% ethanol/96% normal saline, heating to 60 C, and sonicating, and were cooled to room temperature before they were injected intraperitoneally. Intra-arterial infusion of a small amount of glucose was required to avoid hypoglycemia in 48 hr fasted, atglistatin-treated rats. In these animals plasma glucose concentrations were measured every 15 minutes and a variable infusion of 20% glucose (Pfizer Hospira, Lake Forest, IL) was used to maintain plasma glucose concentrations $3.6-3.7 mM.
The physiologic role of glucocorticoids was assessed in 6 and 48 hr fasted rats by treatment with a glucocorticoid receptor antagonist, mifepristone (Sigma). Following a 2 hr tracer infusion at the rates described above to assess fatty acid, glycerol, glucose, and b-OHB turnover, rats were injected with mifepristone (40 mg/kg) IV. The tracer infusion was continued and the tracer of each of the above substrates was again measured 2 hr after treatment with mifepristone.
Glucose Clamps
Alanine turnover was determined in 48 hr fasted rats following a 2 hr infusion of [2,3,3,3- 2 H 4 ]alanine as described below. Then, in order to match plasma glucose concentrations to those of 16 hr fasted rats, a variable infusion of glucose was begun through an arterial catheter in the same rats, with plasma glucose concentrations checked every 15 min and adjusted to maintain plasma glucose concentrations $6.0 mM. Finally, with the glucose infusion continuing, a tracer dose of [6, [6] [7] [8] [9] [10] [11] [12] [13] [14] C 2 ]2-deoxyglucose was administered through a venous catheter and tissue glucose uptake was determined as described below.
In the hyperinsulinemic-euglycemic clamps, glucose turnover was measured during a basal infusion of [1, 2, 3, 4, 5, 6, H 7 ]glucose as described above. A primed-continuous infusion of Regular insulin (prime 40 mU/kg, continuous infusion rate 4 mU/[kg-min]) was initiated for 150 min, during which plasma glucose concentrations were measured every 10-15 min and a variable infusion of 20% glucose (2.5% [1,2,3,4,5,6,6-2 H 7 ] enriched) was infused to maintain euglycemia ($6 pM). The rats were euthanized with IV pentobarbital immediately at the conclusion of the clamp. 
Flux Measurements
All whole-body substrate turnover rates were calculated using the equation Turnover = ([Tracer APE/Plasma APE]-1)*Infusion rate, where APE designates the atom percent enrichment measured by mass spectrometry as described below. All chemicals used for flux analysis were obtained from Sigma. Turnover of glucose (Perry et al., 2017a ), glycerol (Perry et al., 2015 , and bÀOHB (Perry et al., 2017a) were determined by gas chromatography-mass spectrometry (GC-MS) as we have described. Briefly, both glucose and glycerol were deprotonized with 5 volumes of methanol, derivitized with 3 volumes of 1:1 acetic anhydride:pyridine, heated to 65 C for 20 min, and 1 volume of methanol was added, then GC-MS was used in CI mode to measure glucose enrichment and EI mode to measure glycerol enrichment, with turnover calculated using the equation above. bÀOHB was deprotonized with 5 volumes of methanol and derivitized with 3 volumes of b-butanol 4N HCl, after which the samples were heated to 65 C for 60 min, evaporated under N 2 gas, and resuspented in 100 mL of trifluoroacetic acid:methylene chloride (1:7). Fatty acid turnover was measured by determining the plasma palmitate enrichment by GC-MS. Samples were prepared for measurements of palmitate enrichment by evaporating 25 mL plasma, dissolving in 750 mL 1:1 chloroform:methanol and derivitizing with 250 mL boron trifluoride/methanol, then heating to 100 C for 5 min, adding 2 mL pentane and 1 mL water, and centrifuging at low speed for 5 min. The supernatant was transferred to another vial, dissolved, and resuspended in 100 mL hexane for measurement of palmitate enrichment by GC-MS (CI mode). We then corrected for the percent fatty acids (30%-40% in each study) comprised by palmitate to measure total fatty acid turnover (Vatner et al., 2015) . Alanine turnover was determined in rats infused with [2,3,3,3-2 H 4 ]alanine by preparing samples to measure alanine enrichment by GC/MS (CI mode) using the same protocol as was employed to measure bÀOHB enrichment. GC-MS was then used to determine the m+4 alanine enrichment (retention time 13 C]lactate at the rates described above. Flux analysis was performed in rats confirmed post-absorptive (R8 hr fasted) based on the absence of a portal-systemic glucose gradient ( Figure S1B ). The equations used for calculation of flux ratios, which use the positional enrichment of glucose and isotopomers of total and C4C5C6 glucose to calculate these relative fluxes, are as follows:
where G2 denotes glucose [m+2] arising from the condensation of two [m+1] trioses as follows:
and
where G1 denotes glucose [m+1] and G2 is as calculated in Equation (3).
The derivations of these equations can be found in our previous report (Perry et al., 2017b) . Absolute V PC flux was measured by multiplying the V PC /V EGP ratio by the V EGP (whole-body glucose turnover) measured by dilution of [ 2 H 7 ]glucose. Absolute V CS flux was calculated by dividing V PC by the ratio V PC /V CS . Rates of net hepatic glycogenolysis were calculated by measuring liver glycogen concentrations at the time points indicated and at one hour before or after the relevant time point. Assuming a constant rate of glycogenolysis during that hour, glycogenolysis rates were calculated by measuring the difference in liver glycogen between these time points and dividing by 60 min. The contribution of glycerol to gluconeogenesis was calculated as the difference between EGP and the sum of V PC and the rate of net hepatic glycogenolysis. The V PDH /V CS flux was measured as the ratio of [4,5-13 C 2 ]glutamate / [ 13 C 3 ]alanine in liver, brain, heart, skeletal muscle (gastrocnemius), kidney, WAT, and BAT after a 2 hr infusion of [1, 2, 3, 4, 5, [6] [7] [8] [9] [10] [11] [12] [13] C 6 ]glucose (16.7 mmol/[kg-min] prime for 5 min, 5.6 mmol/[kg-min] continuous infusion) based on the assumptions we have described previously (Shulman et al., 1987) . Alanine enrichment was measured by GC-MS as described above, and glutamate by LC-MS/MS: the samples were homogenized in 500 mL ice-cold methanol using a TissueLyser and filtered through a Nanosep filter. LC-MS/MS (AbSCIEX 6500 QTRAP with a Shimadzu ultrafast liquid chromatography system, negative ion mode) was used to monitor the relevant ion pairs: 
Biochemical Analysis
Plasma glucose was measured enzymatically using the YSI Glucose Analyzer (Yellow Springs, OH). Plasma lactate, triglyceride, and bÀOHB concentrations were measured by COBAS (Roche Diagnostics, Indianapolis, IN). Plasma NEFA were measured enzymatically using a Wako reagent (Wako Diagnostics, Mountain View, CA). Plasma glycerol and alanine concentrations were measured by GC-MS: samples were spiked with a 2 H (alanine) or 13 C (glycerol) internal standard and prepared for GC-MS using the protocols described above, with the ratio of labeled to unlabeled substrate compared to a standard curve to measure absolute concentrations. Plasma amino acid concentrations (glycine, alanine, serine, leucine, isoleucine, aspartate+asparagine, phenylalanine, glutamate+glutamine) were measured by GC-MS after spiking with 2 H or 13 C internal standards and derivitizing using the protocol described above for bÀOHB measurements (Leimer et al., 1977) . Plasma insulin, leptin, CRH, ACTH, corticosterone, corticosteroid binding globulin, epinephrine, norepinephrine, growth hormone, T 3 , and FGF-21 concentrations were measured by ELISA (Mercodia, Winston-Salem, NC; Abcam, Cambridge, MA; MyBioSource, San Diego, CA; MyBioSource; Alpco, Salem, NH; MyBioSource; Abnova; Abnova; Millipore, Billerica, MA; MyBioSource; and R&D Systems, Minneapolis, MN, respectively). Plasma insulin concentrations in the hyperinsulinemic-euglycemic clamps (and corresponding basal plasma) were measured by radioimmunoassay by the Yale Diabetes Research Center Radioimmunoassay Core. Samples used for measurement of epinephrine and norepinephrine were collected into prechilled EDTA-coated tubes. Plasma glucagon was measured in plasma samples collected in prechilled tubes containing aprotinin (0.5 mg/ml), by RIA through the Yale Diabetes Research Center Radioimmunoassay Core.
Tissue Analysis
Liver and muscle glycogen concentrations were assessed using amyloglucosidase digestion (Jurczak et al., 2011) . Liver TAG content was measured using the method of Bligh and Dyer (Bligh and Dyer, 1959) : lipids were extracted from livers using 2:1 chloroform:methanol, and the Sekisui triglyceride-SL reagent was used to measure triglyceride content spectrophotometrically. Liver and muscle DAG content (Yu et al., 2002) and liver acetyl-and malonyl-CoA concentrations (Perry et al., 2015 (Perry et al., , 2017a (Samuel et al., 2004) , gluconeogenic enzyme protein expression (Perry et al., 2015) , ApoB (antibody from Meridian Life Science, Memphis, TN), and PGC1a (antibody from Santa Cruz Biotechnology, Dallas, TX) protein expression were assessed by western blot. Expression of each of these proteins was normalized to GAPDH.
QUANTIFICATION AND STATISTICAL ANALYSIS
Comparisons were performed using the 2-tailed Student's t test (if two groups were compared) or ANOVA (if more than two groups were compared), paired or unpaired as specified in the figure legends, with significance defined as a p value < 0.05. GraphPad Prism 7.0 (San Diego, CA) was used for all statistical analysis. In most cases, n = 6-8 rats per group, unless otherwise indicated in the figure legends. Data are presented as the mean ± SEM. Data are the mean ± SEM of n = 6 per group. In (B-L), data were compared by ANOVA with Bonferroni's multiple comparisons test (control versus etomoxir versus atglistatin, with these three groups compared separately at each time point; control data are duplicated between Figures S4 and S5) . In all panels, data are the mean ± SEM of n = 5-6 per group. In (B-I), data were compared by ANOVA with Bonferroni's multiple comparisons test (control versus etomoxir versus atglistatin, with these three groups compared separately at each time point; control data are duplicated between Figures S4 and S5 ). Data are the mean ± SEM of n = 6-8 per group. In (A-O), comparisons were performed using ANOVA with Bonferroni's multiple comparisons test. In (P-Y) data were compared by the 2-tailed unpaired Student's t test, with the exception of (S), in which the 0 and 120 min time points were compared by the 2-tailed paired Student's t test. 
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